Current study evaluates possible correlations between the content of various cell populations, the genetic material of the virus and antibodies to it in the blood of patients and the risk of thrombosis development in patients with acute CMV infection.

А new method for the early detection of immunological and clinical signs of thromboembolic complications of CMV infection in immunocompetent individuals and the treatment of patients in this category will be developed.

• evaluate the immune status main indicators that characterize the activation of immune system, immunosuppression and anergy (myeloid suppressor cells, T-regulatory cells, T-cells according to the stages of differentiation (naive - effector - memory), activated T-cells);
• identify and characterize immunological disorders in patients with CMV infection complicated by thromboembolism of various localization;
• determine the presence and quantitative content in plasma / serum and neutrophils of the CMV genetic material by real-time PCR;
• study humoral immunity to CMV (IgM / IgG antibodies to CMV in serum);
• determine the content of CMV specific T-cells in peripheral blood;
• develop a method for the early detection of immunological and clinical signs of thromboembolic complications of CMV infection in immunocompetent persons and treatment of patients in this category.

Inclusion Criteria:

• age 18 - 80 years;
• fever of not clear etiology
• confirmed CMV infection

Exclusion Criteria:

• HIV infection
• taking hormones, cytostatics;
• drug addiction
• malignant neoplasms over the past 5 years.
• active viral hepatitis or liver cirrhosis;
• immunosuppressive conditions of any etiology

Patients with CMV infection